NAVCO Pharmaceuticals Inc (TSXV:NAV) remains a very small, largely inactive company on the TSX Venture Exchange. Its antimicrobial consumer health products have not translated into reported Revenue for several years, recent filings show modest ongoing losses, and its auditor has raised doubt about its ability to continue as a going concern.

What the company does

NAVCO is based in Vancouver and describes itself as a developer of consumer health and wellness products aimed at protection against viruses, bacteria and other infectious agents. Its range, built around nanotechnology such as nanosilver, has included aerosol sprays, hand sanitiser, hand cream, a product called nano BioGuard-Silver and MunoStrips sublingual strips. Target markets have included personal skin care, household and institutional cleaning, and veterinary health.

The company came to market through a qualifying transaction, the route by which a Capital pool company acquires an operating Business on the TSX Venture Exchange. Its common shares trade under the symbol NAV. Geoffrey Lee is Chief Executive Officer, with Christopher Cooper as Chief Financial Officer and Marek Jasinski as Chief Operating Officer. The financial year runs to 30 September.

What the numbers show

Data from the company's filings show no revenue in the 2023, 2024 or 2025 financial years, after small sales of about $0.06 million in 2022. The net loss narrowed sharply, from about $1.72 million in the year to September 2024 to roughly $79,000 in the year to September 2025, and to around $70,000 for the twelve months to 30 June 2026. All figures are in Canadian dollars.

That reduction reflects much lower spending rather than commercial progress. At 30 June 2026, the company held only nominal cash against liabilities of roughly $680,000, leaving negative shareholders' equity. In January 2026, alongside its annual results, the auditor's report flagged going-concern doubt.

Market signals

The shares have traded at around half a cent, and the Market Value was under $1 million in late October 2026. Trading appears thin, with quoted opening, high and low prices identical on recent sessions.

Health Canada licences were reported in September 2024 for an antimicrobial nanosilver skin product and a nanoparticle antimicrobial cream. However, there is no evidence since then of a product launch, distribution agreement or financing large enough to change the company's position.

What this means

NAVCO's profile now resembles that of a dormant issuer rather than an operating pharmaceutical business. Losses are small because activity is minimal, but without revenue or fresh capital the company cannot repay its liabilities from its own resources. Any revival would most likely require a new financing, a restructuring or a change of business, none of which has been announced.

The limited public disclosure is itself an important part of the picture. Beyond routine financial filings, the company has issued little news, which makes it hard to assess management's plans for the licensed products.

Risks and milestones

The principal risks are insolvency, dilution from any Equity raise at very low prices, and the possibility of regulatory action if continuous-disclosure obligations are missed. Thin trading also means prices may not reflect fundamentals. The next scheduled milestone is the audited annual filing for the year ended 30 September 2026, which would normally be due by late January 2027.